March 18 Quick Takes: Duo of Phase III data for Pfizer; plus Sage, Allergan-AbbVie, Merck, DermTech, Beijing Tide-Insilico

Dermatitis, pneumonia vaccine data for Pfizer
Pfizer Inc. (NYSE:PFE) reported Phase III data for atopic dermatitis therapy abrocitinib and pneumococcal vaccine 20vPnC Wednesday. The JAK-1 inhibitor met the co-primary efficacy endpoints vs. placebo in the JADE COMPARE trial, the third positive readout for the dermatology therapy. The

Read the full 466 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers